Literature DB >> 11264348

Inhibition of human immunodeficiency virus type 1 (HIV-1) replication by HIV-1-based lentivirus vectors expressing transdominant Rev.

M R Mautino1, N Keiser, R A Morgan.   

Abstract

Retrovirus vectors expressing transdominant-negative mutants of Rev (TdRev) inhibit human immunodeficiency virus type 1 (HIV-1) replication by preventing the nuclear export of unspliced viral transcripts, thus inhibiting the synthesis of Gag-Pol, Env, and genomic RNA. The use of HIV-1-based vectors to express TdRev would have the advantage of allowing access to nondividing hematopoietic cells. It would also provide additional levels of protection by sequestering the viral regulatory proteins Tat and Rev, competing for encapsidation into wild-type virions, and inhibiting reverse transcription. Here we describe HIV-1-based vectors that express TdRev. These vectors contain mutations in the splicing signals or replacement of the Rev-responsive element by the simian retrovirus type 1 constitutive transport element, making them less sensitive to the inhibitory effects of TdRev. In addition, overexpression of Rev and the use of an HIV-1 helper plasmid that drives high levels of Gag-Pol synthesis were used to transiently overcome the inhibition by TdRev of the synthesis of Gag-Pol during vector production. SupT1 cells transduced with these vectors were more resistant to HIV-1 replication than cells transduced with Moloney murine leukemia virus-based vectors expressing TdRev. Furthermore, we show that these vectors can be mobilized by the wild-type virus, reducing the infectivity of virions escaping inhibition and conferring protection against HIV-1 replication to previously untransduced cells.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11264348      PMCID: PMC114850          DOI: 10.1128/JVI.75.8.3590-3599.2001

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  44 in total

1.  Improved titers of HIV-based lentiviral vectors using the SRV-1 constitutive transport element.

Authors:  M R Mautino; N Keiser; R A Morgan
Journal:  Gene Ther       Date:  2000-08       Impact factor: 5.250

2.  Potent inhibition of human immunodeficiency virus type 1 replication by conditionally replicating human immunodeficiency virus-based lentiviral vectors expressing envelope antisense mRNA.

Authors:  M R Mautino; R A Morgan
Journal:  Hum Gene Ther       Date:  2000-09-20       Impact factor: 5.695

3.  trans-dominant inhibition of human immunodeficiency virus type 1 Rev occurs through formation of inactive protein complexes.

Authors:  T J Hope; N P Klein; M E Elder; T G Parslow
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

4.  Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone.

Authors:  A Adachi; H E Gendelman; S Koenig; T Folks; R Willey; A Rabson; M A Martin
Journal:  J Virol       Date:  1986-08       Impact factor: 5.103

5.  A Rev-independent human immunodeficiency virus type 1 (HIV-1)-based vector that exploits a codon-optimized HIV-1 gag-pol gene.

Authors:  E Kotsopoulou; V N Kim; A J Kingsman; S M Kingsman; K A Mitrophanous
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

6.  Modified human immunodeficiency virus-based lentiviral vectors display decreased sensitivity to trans-dominant Rev.

Authors:  M R Mautino; W J Ramsey; J Reiser; R A Morgan
Journal:  Hum Gene Ther       Date:  2000-04-10       Impact factor: 5.695

7.  Anti-human immunodeficiency virus type 1 gene therapy in human central nervous system-based cells: an initial approach against a potential viral reservoir.

Authors:  M Mukhtar; H Duke; M BouHamdan; R J Pomerantz
Journal:  Hum Gene Ther       Date:  2000-01-20       Impact factor: 5.695

8.  Gene therapy targeting cord blood-derived CD34+ cells from HIV-exposed infants: preclinical studies.

Authors:  X Li; A Gervaix; D Kang; P Law; S A Spector; A D Ho; F Wong-Staal
Journal:  Gene Ther       Date:  1998-02       Impact factor: 5.250

9.  Immunodeficiency virus rev trans-activator modulates the expression of the viral regulatory genes.

Authors:  M H Malim; J Hauber; R Fenrick; B R Cullen
Journal:  Nature       Date:  1988-09-08       Impact factor: 49.962

10.  Comparison of trans-dominant inhibitory mutant human immunodeficiency virus type 1 genes expressed by retroviral vectors in human T lymphocytes.

Authors:  I Bahner; C Zhou; X J Yu; Q L Hao; J C Guatelli; D B Kohn
Journal:  J Virol       Date:  1993-06       Impact factor: 5.103

View more
  3 in total

1.  Lentiviral delivery of short hairpin RNAs protects CD4 T cells from multiple clades and primary isolates of HIV.

Authors:  Sang-Kyung Lee; Derek M Dykxhoorn; Priti Kumar; Shahin Ranjbar; Erwei Song; Laura E Maliszewski; Vanessa François-Bongarçon; Anne Goldfeld; N Manjunath Swamy; Judy Lieberman; Premlata Shankar
Journal:  Blood       Date:  2005-04-14       Impact factor: 22.113

2.  Rev-free HIV-1 gene delivery system for targeting Rev-RRE-Crm1 nucleocytoplasmic RNA transport pathway.

Authors:  Narasimhachar Srinivasakumar
Journal:  PLoS One       Date:  2011-12-02       Impact factor: 3.240

3.  Long-term vector integration site analysis following retroviral mediated gene transfer to hematopoietic stem cells for the treatment of HIV infection.

Authors:  Jun Hayakawa; Kareem Washington; Naoya Uchida; Oswald Phang; Elizabeth M Kang; Matthew M Hsieh; John F Tisdale
Journal:  PLoS One       Date:  2009-01-16       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.